1. Home
  2. GGT vs CHRS Comparison

GGT vs CHRS Comparison

Compare GGT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Multi-Media Trust Inc. (The)

GGT

Gabelli Multi-Media Trust Inc. (The)

N/A

Current Price

$4.10

Market Cap

175.2M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.36

Market Cap

177.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGT
CHRS
Founded
1994
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.2M
177.7M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
GGT
CHRS
Price
$4.10
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
309.8K
1.2M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
15.56%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$5.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$1.09
52 Week High
$4.39
$2.62

Technical Indicators

Market Signals
Indicator
GGT
CHRS
Relative Strength Index (RSI) 46.83 52.28
Support Level $4.09 $1.34
Resistance Level $4.27 $1.48
Average True Range (ATR) 0.04 0.11
MACD -0.00 0.02
Stochastic Oscillator 18.75 76.92

Price Performance

Historical Comparison
GGT
CHRS

About GGT Gabelli Multi-Media Trust Inc. (The)

Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: